EVEREST MED.LTD DL-0001
Everest Medicines Limited, a biopharmaceutical company, engages in the discovery, license-in, development, and commercialization of therapies and vaccines to address critical unmet medical needs in Greater China and other Asia Pacific markets. Its pipeline includes Nefecon, an oral formulation of budesonide for the treatment of immunoglobulin nephropathy (IgAN); Xerava, a fully synthetic fluorocy… Read more
EVEREST MED.LTD DL-0001 (6HN) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, EVEREST MED.LTD DL-0001 (6HN) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
EVEREST MED.LTD DL-0001 - Net Assets Trend (None–None)
This chart illustrates how EVEREST MED.LTD DL-0001's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for EVEREST MED.LTD DL-0001 (None–None)
The table below shows the annual net assets of EVEREST MED.LTD DL-0001 from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to EVEREST MED.LTD DL-0001's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
EVEREST MED.LTD DL-0001 Competitors by Market Cap
The table below lists competitors of EVEREST MED.LTD DL-0001 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
China Meheco Co Ltd
SHG:600056
|
$1.02 Billion |
|
Bangchak Corporation Public Company Limited
BK:BCP-R
|
$1.02 Billion |
|
Pilot Corporation
OTCGREY:POGHF
|
$1.02 Billion |
|
Lincoln Educational Services
NASDAQ:LINC
|
$1.02 Billion |
|
Juventus Football Club S.p.A
PINK:JVTSF
|
$1.02 Billion |
|
Goosehead Insurance Inc
NASDAQ:GSHD
|
$1.02 Billion |
|
Odfjell Drilling Ltd
OL:ODL
|
$1.02 Billion |
|
Nuvation Bio Inc
NYSE:NUVB
|
$1.02 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in EVEREST MED.LTD DL-0001's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares EVEREST MED.LTD DL-0001's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently EVEREST MED.LTD DL-0001 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares EVEREST MED.LTD DL-0001's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,291,084,078
- Average return on equity (ROE) among peers: -24.49%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| EVEREST MED.LTD DL-0001 (6HN) | €- | N/A | N/A | $1.02 Billion |
| 09R (09R) | $-3.01 Million | 0.00% | 0.00x | $11.12 Million |
| IDORSIA AG (19T) | $-968.72 Million | 0.00% | 0.00x | $532.51 Million |
| 1S90 (1S90) | $-44.86 Million | 0.00% | 0.00x | $51.72 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.31 Million |
| 25K0 (25K0) | $-16.66 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $-37.78 Million | 0.00% | 0.00x | $6.23 Million |
| Intervacc AB (publ) (2E9) | $237.93 Million | -43.23% | 0.09x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $14.92 Million | -17.30% | 0.56x | $9.25 Million |
| GNI Group Ltd (3G6) | $13.72 Billion | -1.46% | 0.26x | $772.60 Million |